Obesity

Weight management therapies including GLP-1 receptor agonists, dual agonists, and metabolic modulators.

Companies

Pipeline Drugs

120

Key People

115

Obesity Pipeline (120 drugs)

Commercial: 27Approved/Commercial: 15Phase 2: 13Approved: 12Phase 3: 12Phase 1: 11Phase 2/3: 5Preclinical: 3Pre-clinical: 3Discovery: 3Phase 2b: 2IND-Enabling: 2Optimization: 2Phase 1-3: 1Phase 1/2: 1Phase 1b: 1Preclinical/Phase 1: 1Not specified: 1Phase 1 Completed: 1Research: 1Early Feasibility: 1Pivotal: 1R&D: 1

Drug	Company	Indication	Phase	Status
Tirzepatide (Mounjaro)	Eli Lilly	Type 2 Diabetes	Approved	Commercial
Tirzepatide (Zepbound)	Eli Lilly	Obesity	Approved	Commercial
Donanemab	Eli Lilly	Alzheimer's Disease	Phase 3	Regulatory Review
Mirikizumab	Eli Lilly	Ulcerative Colitis	Phase 3	Active
Lebrikizumab	Eli Lilly	Atopic Dermatitis	Phase 3	Active
Orforglipron	Eli Lilly	Type 2 Diabetes	Phase 3	Active
Pirtobrutinib	Eli Lilly	B-cell Malignancies	Phase 3	Active
Retifanlimab	Eli Lilly	Various Cancers	Phase 2/3	Active
Verzenio (abemaciclib)	Eli Lilly	Breast Cancer	Approved	Commercial
Jardiance (empagliflozin)	Eli Lilly	Diabetes/Heart Failure	Approved	Commercial
Trulicity (dulaglutide)	Eli Lilly	Type 2 Diabetes	Approved	Commercial
Taltz (ixekizumab)	Eli Lilly	Psoriasis	Approved	Commercial
Emgality (galcanezumab)	Eli Lilly	Migraine	Approved	Commercial
BGE-102	BioAge Labs	Cardiovascular Risk and Metabolic Dysfunction	Phase 1	Active
APJ Program	BioAge Labs	Obesity	Preclinical	Active
Wegovy HD (semaglutide 7.2mg)	Novo Nordisk	Obesity	Approved	Recently approved in US
Glucose-sensitive insulin analogue	Novo Nordisk	Type 1 & 2 Diabetes	Phase 1	Active
siRNA GalXC-GYS2	Novo Nordisk	Type 2 Diabetes	Phase 1	Active
Amylin analogue (subcutaneous)	Novo Nordisk	Obesity	Phase 1	Active
CNP analogue	Novo Nordisk	Heart Failure	Phase 1	Active
NLRP3 inhibitor	Novo Nordisk	Cardiovascular Disease	Phase 1	Active
siRNA SLC25A5	Novo Nordisk	MASH	Phase 1	Active
Oral antibody fragment	Novo Nordisk	Haemophilia	Phase 1	Active
Subcutaneous Zenagamtide	Novo Nordisk	Multiple indications	Phase 2	Active
CB1 receptor blocker	Novo Nordisk	Diabetic Kidney Disease	Phase 2	Active
Oral GLP-1/amylin co-agonist	Novo Nordisk	Diabetes/Obesity	Phase 2	Active
Triple agonist (GLP-1/GIP/glucagon)	Novo Nordisk	Obesity/Type 2 Diabetes	Phase 2	Active
GLP1-GIP-Amylin tri-agonist	Novo Nordisk	Obesity	Phase 2	Active
Anti-miR-132 ASO	Novo Nordisk	Heart Failure	Phase 2	Active
Decitabine combination	Novo Nordisk	Sickle Cell Disease	Phase 2	Active
PKR activator	Novo Nordisk	Thalassemia	Phase 2	Active
Amylin/semaglutide combination	Novo Nordisk	Type 2 Diabetes	Phase 3	Active
Long-acting amylin analogue	Novo Nordisk	Multiple indications	Phase 3	Active
Comirnaty (COVID-19 Vaccine)	Pfizer	SARS-CoV-2 Prevention	Approved	Commercial
Paxlovid	Pfizer	COVID-19 Treatment	Approved	Commercial
Elrexfio	Pfizer	Multiple Myeloma	Approved	Commercial
Abrysvo	Pfizer	RSV Prevention	Approved	Commercial
Obesity Pipeline Programs	Pfizer	Weight Management	Phase 2/3	Active
Oncology Portfolio	Pfizer	Various Cancers	Phase 1-3	Multiple Active Programs
Type 2 Diabetes Therapies	Pfizer	Diabetes Management	Phase 2/3	Active
Cardiovascular Treatments	Pfizer	Heart Disease	Phase 2/3	Active
Inflammation & Immunology Programs	Pfizer	Autoimmune Diseases	Phase 2/3	Active
IMCIVREE (setmelanotide)	Rhythm Pharmaceuticals	POMC deficiency obesity	Commercial	Approved
Setmelanotide	Rhythm Pharmaceuticals	Prader-Willi syndrome	Phase 3	Active
RM-718	Rhythm Pharmaceuticals	Congenital hyperinsulinism	Pre-clinical	Active
VK2735 (subcutaneous)	Viking Therapeutics	Obesity	Phase 3	Active
VK2735 (oral)	Viking Therapeutics	Obesity	Phase 1/2	Active
VK2809	Viking Therapeutics	Lipid and metabolic disorders	Phase 2b	Active
VK0214	Viking Therapeutics	X-linked adrenoleukodystrophy (X-ALD)	Phase 1b	Active
VK5211	Viking Therapeutics	Muscle wasting/aging	Preclinical/Phase 1	Development